Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Samsara Inc (IOT) vs Viatris Inc (VTRS) Price & Performance

Samsara IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Samsara Inc vs Viatris Inc — how do they compare? Samsara Inc trades at $36.4 (market cap $22.46B), while Viatris Inc trades at $17.3 (market cap $19.79B). The key difference: Samsara Inc and Viatris Inc are close in size by market cap, and Viatris Inc pays a 2.83% dividend while Samsara Inc pays none. Which is the better fit depends on your goals.

IOTVTRS
Market Cap
$22.46B$19.79B
Sector
TechnologyHealth
52-Week High
$45.22$17.39
52-Week Low
$24.25$8.74
Enterprise Value
$21.73B$32.00B
Dividend Yield
2.83%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Samsara Inc

Samsara (IOT) trades at $38.55, up 0.6% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings momentum with three consecutive quarterly beats, while revenue growth accelerated to $1.7B in 2026 with positive net income of $58M. Technical indicators show bullish moving averages despite overbought RSI readings, with key resistance at $39-$41. Recent product launches including AI agentic tools and tracking labels demonstrate continued innovation in connected operations.

The outlook remains positive with 78% analyst buy ratings and $44.40 consensus target offering 15% upside. However, elevated valuations (P/E 383) and negative 2025 cash flow (-$59M) present risks. Growth sustainability depends on maintaining large customer momentum and margin expansion amid AI investments. The stock presents a growth opportunity but requires monitoring of execution and valuation compression risks.

Viatris Inc

Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.

Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Samsara Inc

Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.

Read more on IOT

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS